BioCryst Pharmaceuticals (BCRX)
(Delayed Data from NSDQ)
$7.52 USD
-0.33 (-4.20%)
Updated Jul 29, 2024 04:00 PM ET
After-Market: $7.51 -0.01 (-0.13%) 7:58 PM ET
1-Strong Buy of 5 1
F Value C Growth F Momentum F VGM
Industry / Sector Report
Industry : Medical - Drugs
Zacks Industry Rank
Top 39% (97 out of 251)Zacks Sector Rank
Top 31% (5 out of 16)Recommendations and Estimates
Company | Industry | SP500 | |
---|---|---|---|
Average Recommendation (1=Buy, 5=Sell) | 1.50 | 1.52 | 9.99 |
Current Quarter Estimate | -0.19 | -2.04 | 61.00 |
Year Ago Quarter Estimate | -0.24 | -0.59 | 54.84 |
Next Quarter Estimate | -0.15 | -2.00 | 63.00 |
Next Year Estimate | -0.35 | 6.92 | 270.00 |
Growth Rates
Company | Industry | SP500 | |
---|---|---|---|
This Year | 35.00 | 13.60 | 15.67 |
Next Year | 46.15 | 16.10 | 9.31 |
Last 5 Years | -386.40 | 7.00 | 8.10 |
Next 5 Years | 40.40 | 25.50 | NA |
Financials
Company | Industry | |
---|---|---|
Price/Earnings (TTM) | NA | -5.88 |
Price/Book (MRQ) | NA | 1.82 |
Price/Cash Flow (MRFY) | NA | 8.53 |
Dividend Yield | 0.00% | 0.00% |
Net Profit Margin (TTM) | -58.69% | -315.56% |
Return on Equity (TTM) | NA | -82.03% |
Debt to Equity (MRQ) | NA | 0.04 |
MRQ = Most Recent Quarter
TTM = Trailing Twelve Months
MRFY = Most Recent Fiscal Year
Note: Company and S&P 500 ratios relating to share price calculated daily; all others calculated weekly or in accordance with company earnings announcement. Industry medians calculated weekly.